Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística

Show other versions (1)

Bibliographic Details
Main Author:	Paula Del Río Ortega
Format:	Article
Language:	English
Published:	Fundación Pharmaceutical Care España 2022-03-01
Series:	Pharmaceutical Care España
Online Access:	https://pharmcareesp.com/index.php/PharmaCARE/article/view/721

Similar Items

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022-03-01)

USO DE EXACAFTOR/ TEZACAFTOR /IVACAFTOR EN PACIENTES CON FIBROSIS QUÍSTICA POST-TRASPLANTE PULMONAR
by: Pablo Jorquera Pinto
Published: (2023-03-01)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
by: Lijia Zhang, et al.
Published: (2022-12-01)

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
by: Hazel Ozuna, et al.
Published: (2025-01-01)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024-06-01)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
by: Shiferaw D, et al.
Published: (2019-08-01)

Efectividad de ivacaftor en vida real en niños con fibrosis quística y mutación G551D
by: David Gomez-Pastrana, et al.
Published: (2019-03-01)

Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
by: Tahuanty A. Pena, MD, MS, et al.
Published: (2025-02-01)

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
by: Marta Solís García, et al.
Published: (2025-02-01)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
by: Ryan Marsh, et al.
Published: (2023-10-01)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
by: Sarah Allgood, et al.
Published: (2023-09-01)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023-04-01)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
by: Sophia T. Pallenberg, et al.
Published: (2022-10-01)

Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
by: Shiferaw D, et al.
Published: (2019-10-01)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023-03-01)

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
by: Varun Garg, et al.
Published: (2019-05-01)

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
by: Seth A. Reasoner, et al.
Published: (2024-02-01)

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
by: Andrea Gramegna, et al.
Published: (2023-06-01)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023-03-01)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
by: Dirk Westhölter, et al.
Published: (2023-02-01)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
by: Payal Patel, et al.
Published: (2023-02-01)

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis
by: Thomas Keens, et al.
Published: (2024-04-01)

Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
by: Harish Pudukodu, et al.
Published: (2024-09-01)

Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis
by: Dirk Westhölter, et al.
Published: (2024-01-01)

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
by: Christian Martin, et al.
Published: (2023-12-01)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022-08-01)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
by: Marika Comegna, et al.
Published: (2021-07-01)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
by: Elena Stekolchik, et al.
Published: (2022-01-01)

Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)
by: Mahan Salehi, et al.
Published: (2021-01-01)

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis
by: Carlos Martín de Vicente, et al.
Published: (2024-12-01)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
by: Sherstin T. Lommatzsch, et al.
Published: (2019-04-01)

Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy
by: Yasmin Hilliam, et al.
Published: (2024-08-01)

One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis
by: Aubriot Anne-Sophie, et al.
Published: (2024-03-01)

Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
by: Kadambari Vijaykumar, et al.
Published: (2024-04-01)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
by: Mafalda Bacalhau, et al.
Published: (2023-03-01)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
by: Renate Kos, et al.
Published: (2022-12-01)

CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
by: Hanna Crow, et al.
Published: (2022-12-01)

Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis
by: Christine L. Chan, et al.
Published: (2022-12-01)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del.
by: Heledd H Jarosz-Griffiths, et al.
Published: (2024-01-01)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del
by: Heledd H. Jarosz-Griffiths, et al.
Published: (2024-01-01)